A Phase 2 interventional study of KYV-101 and Standard lymphodepletion regimen in Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive and Multiple Sclerosis, sponsored by Kyverna Therapeutics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Kyverna Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 27th largest by planned enrollment of the 85 interventional ones that give a count, is one of 11 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 19 of the 37 other live ones, and was the 73rd registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:
University of Iowa · Sites in United States
Ages 45–70
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Zenas BioPharma (USA), LLC · Sites in United States, Australia, Bulgaria and 15 more countries
Ages 18–60
Zenas BioPharma (USA), LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 32 · Phase 3 22 · Phase 4 1
First in 2002; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 59 across the 85 interventional studies, 125 across the 20 observational. Of the 62 that completed or were terminated, 28 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 105 have an industry lead sponsor. The 10 most frequent:
Kyverna Therapeutics is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Kyverna Therapeutics has 1 study filed under Multiple Sclerosis, Chronic Progressive — fewer than ten, so there is no comparison to draw.
10 of the studies in Multiple Sclerosis, Chronic Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT03109288National Institute of Allergy and Infectious Diseases (NIAID)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | 2027-01-01 |
| NCT07270120Ohio State UniversitySenolytics for Secondary Progressive MS | 2027-01-15 |
| NCT05122559Emmanuelle Waubant, MD PhDNeuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | 2027-02 |
| NCT06384976Kyverna TherapeuticsKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | 2027-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease in which lymphocytes at first attack the myelin sheaths within the central nervous system (CNS), accompanied or later followed by axonal damage. B cells play a central and multifunctional role in the immunopathogenesis of MS. B cells present antigen to T cells in stimulating a pro-inflammatory immune cascade, secrete pathogenic cytokines, moderate T cell and myeloid cell functions, form structural B cell meningeal follicles within the human central nervous system and produce pathogenic antibodies upon evolution to plasma cells.
CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory primary and secondary progressive multiple sclerosis.
Key Inclusion Criteria:
Key Exclusion Criteria:
Previous or concurrent with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing with KYV-101 CAR T cells
Biological: KYV-101 · Drug: Standard lymphodepletion regimen
Dosing with anti-CD20 mAb
Drug: Anti-CD20 mAB
Anti-CD19 CAR-T cell therapy
CYC/FLU
Anti-CD20 mAB
To evaluate efficacy of KYV-101
Confirmed disability Progression on the EDSS scale. The EDSS scale ranges from 0 to 10 in 0.5- unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist.
Time frame: at least 12 weeks
To characterize the safety and tolerability of KYV-101
Incidence and severity of adverse events (AEs)
Time frame: Up to 2 years
To characterize the safety and tolerability of KYV-101
Incidence and severity of adverse events of special interests (AESIs)
Time frame: Up to 2 years
To characterize the safety and tolerability of KYV-101
Incidence and severity of serious adverse events (SAEs)
Time frame: Up to 2 years
To evaluate efficacy of KYV-101
Composite Confirmed Disability Progression (CCPD)
Time frame: up to 12 weeks
To characterize the pharmacokinetics (PK)
Levels of Chimeric antigen receptor positive (CAR-positive) T cell counts
Time frame: Up to 2 years
To characterize the pharmacokinetics (PK)
Levels of CAR Transgene levels
Time frame: Up to 2 years
To characterize the Pharmacodynamics (PD)
Levels of B cell in the blood
Time frame: Up to 2 years
To characterize the Pharmacodynamics (PD)
Serum cytokines will be measured by multiplexed mesoscale discovery (MSD) assay and will include cytokines historically associated with potential CAR T toxicity (CRS and ICANS) such as gamma interferon (IFNg) and interleukin 6 (IL-6).
Time frame: Up to 2 years
To evaluate the immunogenicity (humoral response) of KYV-101
Percentage of participants who develop anti-KYV-101 antibodies by immunoassays)
Time frame: Up to 2 years
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mivocabtagene autoleucel
Multiple Sclerosis, Chronic Progressive →
Kyverna Therapeutics